The United Laboratories International Holdings Ltd. (ULIHF)
0.9419
0.00 (0.00%)
USD |
OTCM |
Oct 28, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.856B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -48.22% |
| Valuation | |
| PE Ratio | 23.97 |
| PE Ratio (Forward) | |
| PS Ratio | 1.095 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | 0.0381 |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 54.27% |
Profile
| The United Laboratories International Holdings Ltd. engages in manufacturing and selling medicine products. It operates through the following segments: Intermediate Products, Bulk Medicine, and Finished Products. The Intermediate Products segment represents sales of 6-aminopenicillanic acid (6-APA) products and penicillin G potassium products. The Bulk Medicine segment covers the sales of amoxicillin products. The Finished Products segment sells insulin series products, antibiotics products, ophthalmic products, veterinary drugs, and license fee income. The company was founded in 1990 and is headquartered in Hong Kong. |
| URL | http://www.tul.com.cn |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Value |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 09, 2026 |
Profile
| The United Laboratories International Holdings Ltd. engages in manufacturing and selling medicine products. It operates through the following segments: Intermediate Products, Bulk Medicine, and Finished Products. The Intermediate Products segment represents sales of 6-aminopenicillanic acid (6-APA) products and penicillin G potassium products. The Bulk Medicine segment covers the sales of amoxicillin products. The Finished Products segment sells insulin series products, antibiotics products, ophthalmic products, veterinary drugs, and license fee income. The company was founded in 1990 and is headquartered in Hong Kong. |
| URL | http://www.tul.com.cn |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Value |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 09, 2026 |